```html

Zollinger‑Ellison Syndrome (Gastric & Duodenal Ulcer Disease)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas develop in the pancreas or duodenum. These neuroendocrine tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of gastric acid. The resulting hyperacidity overwhelms the protective mechanisms of the stomach and duodenum, leading to multiple, often refractory gastric and duodenal ulcers.

Who it affects: ZES can occur at any age but most commonly presents in adults aged 30‑60 years. Both men and women are affected, with a slight male predominance (≈55 % male). Approximately 25 % of cases are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN‑1), while the remaining 75 % are sporadic.

Prevalence: The incidence is estimated at 0.5–2 cases per million people per year worldwide (Mayo Clinic Proceedings, 2013). Because the disease is rare and often misdiagnosed, the true prevalence may be under‑reported.

Symptoms

Symptoms stem from excess gastric acid, tumor mass effect, and complications of ulcers. The presentation may be abrupt or develop gradually over months.

• Abdominal pain – Burning or gnawing pain, often 2–3 hours after meals or at night when acid secretion peaks.
• Diarrhea – Acid inactivates pancreatic enzymes and damages the intestinal mucosa, resulting in watery, sometimes greasy stools.
• Steatorrhea – Fatty stools due to malabsorption of fat.
• Nausea & vomiting – May be precipitated by ulcer perforation or severe gastritis.
• Weight loss – From malabsorption, chronic diarrhea, and decreased appetite.
• Gastroesophageal reflux disease (GERD) – Heartburn and regurgitation that are refractory to standard therapy.
• Upper gastrointestinal bleeding – Hematemesis (vomiting blood) or melena (black, tarry stools) from ulcer erosion.
• Perforated ulcer – Sudden, severe abdominal pain with peritoneal signs (rigid abdomen).
• Obstruction – Large ulcer or tumor may cause gastric outlet or duodenal obstruction, leading to vomiting of undigested food.
• MEN‑1 manifestations (if present) – Hyperparathyroidism (kidney stones, bone pain), pituitary adenomas (headaches, vision changes).

Because the ulcers can occur downstream of the duodenum, patients may develop “atypical” ulcer locations, such as in the jejunum, which is a clue to ZES.

Causes and Risk Factors

Underlying cause

ZES is caused by a gastrin‑producing neuroendocrine tumor (gastrinoma). The majority are sporadic and arise from the “gastrinoma triangle” (pancreatic head, duodenal bulb, and the junction of the second and third portions of the duodenum). A smaller subset is hereditary, occurring as part of MEN‑1, an autosomal‑dominant syndrome caused by mutations in the MEN1 tumor suppressor gene.

Risk factors

• Family history of MEN‑1 or known MEN1 mutation.
• Previous diagnosis of pancreatic or duodenal neuroendocrine tumor.
• Age > 30 years – Most sporadic gastrinomas are diagnosed after the third decade.
• Chronic use of proton pump inhibitors (PPIs) – While PPIs treat the acid hypersecretion, long‑term use may mask symptoms, leading to delayed diagnosis. They are not a cause but a confounder.

Diagnosis

Diagnosing ZES requires a combination of clinical suspicion, biochemical testing, imaging, and endoscopic evaluation.

1. Biochemical tests

• Fasting serum gastrin level – A level > 1,000 pg/mL (≥5× the upper limit) in the presence of gastric acidity is highly suggestive. Values between 200‑1,000 pg/mL are interpreted with the secretin stimulation test.
• Secretin stimulation test – Intravenous secretin normally suppresses gastrin; in ZES, gastrin paradoxically rises ≥120 pg/mL. Sensitivity ≈94 % and specificity ≈90 % (NEJM, 2005).
• Acid output measurement – 24‑hour gastric acid collection shows > 15 mEq/h (hypersecretion).

2. Endoscopic assessment

• Upper endoscopy (EGD) – Identifies multiple ulcers, especially beyond the duodenal bulb, and obtains biopsies to rule out H. pylori or malignancy.
• Endoscopic ultrasound (EUS) – Detects small pancreatic or duodenal lesions <2 cm in size.

3. Imaging for tumor localization

• Multiphasic contrast‑enhanced CT or MRI – First‑line cross‑sectional imaging; detects tumors > 1 cm.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – Highly sensitive for neuroendocrine tumors, especially small or occult gastrinomas.
• Selective arterial secretin stimulation test (SASS) – Invasive test used when non‑invasive imaging fails to localize disease.

4. MEN‑1 screening

If MEN‑1 is suspected, genetic counseling and testing for MEN1 mutation are recommended, as well as screening for hyperparathyroidism (serum calcium, PTH) and pituitary lesions (MRI).

Treatment Options

Management aims to (1) control acid hypersecretion, (2) eradicate or control the gastrinoma, and (3) address complications.

1. Acid suppression

• Proton pump inhibitors (PPIs) – High‑dose, long‑acting agents (e.g., omeprazole 60 mg twice daily or equivalent). PPIs are the cornerstone; 80‑90 % of patients achieve ulcer healing (Cleveland Clinic).
• Histamine‑2 receptor antagonists (H2RAs) – May be used as adjuncts but are less effective for the extreme acid output of ZES.

2. Surgical management

• Localized tumor resection – Enucleation or pancreaticoduodenectomy for solitary gastrinomas <2 cm without metastasis.
• Debulking surgery – Reduces tumor burden in metastatic disease; improves symptom control when combined with medical therapy.
• Liver metastasis treatment – Options include hepatic resection, radiofrequency ablation, or hepatic artery embolization.

3. Medical therapies for tumor control

• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin release and may shrink tumor size. Effective in ~30‑40 % of patients.
• Targeted therapy – Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) approved for progressive pancreatic neuroendocrine tumors; used off‑label in ZES when other options fail.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival in neuroendocrine tumors.

4. Lifestyle & supportive measures

• Avoid NSAIDs, aspirin, and alcohol – all increase ulcer risk.
• Small, frequent meals to reduce gastric workload.
• Maintain adequate nutrition; consider pancreatic enzyme supplements if malabsorption is severe.

Living with Zollinger‑Ellison Syndrome (gastric duodenal ulcer disease)

Long‑term management is a partnership between the patient, gastroenterologist, endocrinologist, and surgeon.

Medication adherence

• Take PPIs exactly as prescribed; never skip doses.
• Carry a rescue dose of PPI for breakthrough symptoms.
• Regularly review medication list with your doctor to avoid interactions (e.g., antiretrovirals, antifungals).

Monitoring

• Endoscopy every 1‑2 years to assess ulcer healing and detect new lesions.
• Serum gastrin every 6‑12 months; rising levels may signal tumor progression.
• Imaging (CT/MRI or PET) every 12‑18 months if disease is known to be metastatic.

Nutrition

• High‑protein, low‑fat diet while monitoring for steatorrhea.
• Supplement calcium and vitamin D if long‑term PPI use causes malabsorption.
• Consider a dietitian experienced with neuroendocrine tumors.

Psychosocial support

• Join support groups (e.g., Carcinoid Cancer Foundation) to share experiences.
• Address anxiety or depression with mental‑health professionals—chronic disease can be stressful.

Prevention

Because ZES is largely a sporadic neuroendocrine tumor, primary prevention is limited. However, the following steps can reduce secondary complications:

• Early detection in families with MEN‑1 through genetic counseling and routine screening.
• Avoid chronic use of ulcer‑causing medications (NSAIDs) unless medically necessary.
• Prompt treatment of H. pylori infection, which can exacerbate ulcer disease.
• Adopt a balanced diet low in irritants (spicy foods, caffeine, alcohol) to lessen symptom burden.

Complications

If left untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated ulcer – Free air in the abdomen, peritonitis, and surgical emergency.
• Severe gastrointestinal bleeding – May require transfusion or endoscopic hemostasis.
• Obstruction – Gastric outlet or duodenal blockage causing persistent vomiting.
• Malnutrition & electrolyte disturbances – Due to chronic diarrhea and malabsorption.
• Metastatic gastrinoma – Liver, lymph nodes, or distant organs; reduces long‑term survival.
• Bronchial or pulmonary complications – Acid aspiration can cause chronic cough or pneumonia.
• Increased risk of gastric adenocarcinoma – Prolonged acid exposure may predispose to malignant transformation.

When to Seek Emergency Care

References

1. Mayo Clinic Proceedings. “Zollinger-Ellison Syndrome.” 2013;88(10):1155‑1165. PMCID: PMC3760677
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” Updated 2022. niddk.nih.gov
3. Cleveland Clinic. “Zollinger‑Ellison Syndrome: Diagnosis & Treatment.” 2024. clevelandclinic.org
4. World Health Organization. “Neuroendocrine Tumours.” WHO Classification of Tumours. 2022.
5. American College of Gastroenterology. “Guidelines for the Management of Gastric Ulcer Disease.” 2023. gi.org
6. Carcinoid Cancer Foundation. “Zollinger‑Ellison Syndrome Patient Resources.” 2024. carcinoid.org

```